Novartis AG

Swiss Stock Exchange:NOVN.SW

Location

Market Cap

USD 237.63 B

Share Price

USD 120.31

Avg Daily Volume

4,098,771

Change (1 day)

0.29%

Change (1 year)

13.35%

Change (YTD)

22.67%

Novartis AG Shares (Diluted, Weighted) for the year ending December 31, 2024: 2,035,000,000

Novartis AG Shares (Diluted, Weighted) is 2,035,000,000 for the year ending December 31, 2024, a -2.72% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.
  • Novartis AG Shares (Diluted, Weighted) for the year ending December 31, 2023 was 2,092,000,000, a -4.78% change year over year.
  • Novartis AG Shares (Diluted, Weighted) for the year ending December 31, 2022 was 2,197,000,000, a -2.79% change year over year.
  • Novartis AG Shares (Diluted, Weighted) for the year ending December 31, 2021 was 2,260,000,000, a -1.57% change year over year.
  • Novartis AG Shares (Diluted, Weighted) for the year ending December 31, 2020 was 2,296,000,000, a -0.99% change year over year.
Key data
Date Shares (Diluted, Weighted) Selling, General, and Administrative Expenses (SG&A) Research and Development (R&D) Expenses Revenue
Market news
Loading...
Swiss Stock Exchange: NOVN.SW

Novartis AG

CEO Dr. Vasant Narasimhan M.D.
IPO Date Aug. 3, 1995
Location Switzerland
Headquarters Lichtstrasse 35
Employees 75,883
Sector 🏥 Health Care
Industries
Description

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Similar companies

ABBV

AbbVie Inc.

USD 182.31

-2.40%

NOVO-B.CO

Novo Nordisk A/S

USD 68.56

1.71%

RO.SW

Roche Holding AG

USD 347.50

0.20%

ABT

Abbott Laboratories

USD 134.38

0.53%

AZN.L

AstraZeneca PLC

USD 140.24

0.73%

MRK

Merck & Co., Inc.

USD 79.10

0.34%

AMGN

Amgen Inc.

USD 277.13

-0.71%

PFE

Pfizer Inc.

USD 24.19

-0.21%

GILD

Gilead Sciences, Inc.

USD 110.67

2.83%

SAN.PA

Sanofi

USD 96.65

0.37%

VRTX

Vertex Pharmaceuticals Incorporated

USD 441.30

-0.47%

BMY

Bristol-Myers Squibb Company

USD 46.35

-0.64%

4519.T

Chugai Pharmaceutical Co., Ltd.

USD 51.91

-1.13%

GSK.L

GSK plc

USD 19.28

0.69%

CSL.AX

CSL Limited

USD 153.01

-2.58%

MRK.DE

MERCK Kommanditgesellschaft auf Aktien

USD 131.98

1.04%

REGN

Regeneron Pharmaceuticals, Inc.

USD 521.00

0.00%

600276.SS

Jiangsu Hengrui Medicine Co., Ltd.

USD 7.24

-0.32%

4502.T

Takeda Pharmaceutical Company Limited

USD 30.16

-0.03%

ALNY

Alnylam Pharmaceuticals, Inc.

USD 322.83

1.44%

UCB.BR

UCB SA

USD 199.41

0.97%

GEHC

GE HealthCare Technologies Inc.

USD 74.38

-0.64%

BAYN.DE

Bayer AG

USD 31.61

2.81%

068270.KS

Celltrion, Inc.

USD 116.73

-0.46%

2359.HK

WuXi AppTec Co., Ltd.

USD 9.68

-1.75%

3692.HK

Hansoh Pharmaceutical Group Company Limited

USD 3.71

-0.01%

LH

Laboratory Corporation of America Holdings

USD 260.59

1.41%

INSM

Insmed Incorporated

USD 99.49

-2.21%

RPRX

Royalty Pharma plc

USD 35.87

1.70%

BIIB

Biogen Inc.

USD 126.08

-0.66%

4503.T

Astellas Pharma Inc.

USD 9.69

0.99%

1801.HK

Innovent Biologics, Inc.

USD 9.85

-1.60%

SMMT

Summit Therapeutics Inc.

USD 20.60

-3.38%

4507.T

Shionogi & Co., Ltd.

USD 17.51

-0.68%

TORNTPHARM.NS

Torrent Pharmaceuticals Limited

USD 39.09

3.96%

GMAB.CO

Genmab A/S

USD 205.20

-0.79%

NBIX

Neurocrine Biosciences, Inc.

USD 125.42

-1.02%

EXEL

Exelixis, Inc.

USD 43.67

1.35%

MANKIND.NS

Mankind Pharma Limited

USD 27.30

1.56%

603392.SS

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

USD 8.56

0.65%

RGC

Regencell Bioscience Holdings Limited

USD 17.40

-13.82%

9926.HK

Akeso, Inc.

USD 11.78

-2.48%

ASND

Ascendis Pharma A/S

USD 172.22

-0.42%

LUPIN.NS

Lupin Limited

USD 22.64

0.60%

BMRN

BioMarin Pharmaceutical Inc.

USD 55.17

1.98%

SOBI.ST

Swedish Orphan Biovitrum AB (publ)

USD 29.88

2.57%

IPN.PA

Ipsen S.A.

USD 120.09

-0.15%

000963.SZ

Huadong Medicine Co., Ltd

USD 5.63

0.53%

4151.T

Kyowa Kirin Co., Ltd.

USD 16.88

-1.46%

StockViz Staff

June 30, 2025

Any question? Send us an email